A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Spranger, Stefani ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Checkpoint inhibition; Immune evasion; T cell infiltration; Tumor microenvironment

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; B RAF KINASE; BETA CATENIN; CD103 ANTIGEN; CD8ALPHA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; WNT1 PROTEIN;

CELL INFILTRATION; DENDRITIC CELL; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; IMMUNE EVASION; IMMUNOTHERAPY; METASTATIC MELANOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC ORGANISM; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84997764883     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0089-6     Document Type: Note

References (14)

1. Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral oncology. 2015;51:12-5. doi: 10.1016/j.oraloncology.2014.10.010.
2. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Therapeutic advances in medical oncology. 2013;5:169-81. doi: 10.1177/1758834012475152.
3. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert opinion on biological therapy. 2013;13:847-61. doi: 10.1517/14712598.2013.770836.
4. Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-71. doi: 10.1038/nature13954.
5. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.
6. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231-5. doi: 10.1038/nature14404.
7. Bosenberg M, Muthusamy V, Curley DP, Wang Z, Hobbs C, Nelson B, et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis. 2006;44:262-7. doi: 10.1002/dvg.20205.
8. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer cell. 2011;20:741-54. doi: 10.1016/j.ccr.2011.10.030.
9. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature genetics. 2009;41:544-52. doi: 10.1038/ng.356.
10. Cheung AF, Dupage MJ, Dong HK, Chen J, Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer research. 2008;68:9459-68. doi: 10.1158/0008-5472.CAN-08-2634.
11. Sweis RF, Spranger S, Gajewski TF. Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. Journal of clinical oncology. 2015;33:abstr 4511.
12. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19:393-403. doi: 10.1158/1078-0432.CCR-12-1626.
13. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer immunology research. 2014;2:361-70. doi: 10.1158/2326-6066.CIR-13-0127.
14. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014;20:5527-36. doi: 10.1158/1078-0432.CCR-14-1027.